Have we changed the outcome in membranous nephropathy? A propensity study on the role of immunosuppressive therapy

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 7, 2011, Pages 1591-1598

  Cattran, Daniel C ^a   Reich, Heather N ^a   Joseph Kim, S ^a   Troyanov, Stéphan ^b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; STEROID;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL FEATURE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PROPENSITY SCORE; PROSPECTIVE STUDY; PROTEINURIA; REMISSION; THERAPY EFFECT; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY; MALE; MIDDLE AGED; ONTARIO; PHYSICIAN'S PRACTICE PATTERNS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEINURIA; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960315336     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.11001210     Document Type: Article

References (44)

1. Wirta O, Mustonen J, Helin H, Pasternack A: Incidence of biopsy-proven glomerulonephritis. Nephrol Dial Transplant 23: 193-200, 2008
2. Treatment of End-Stage Organ Failure in Canada, 1997 to 2006, Ottawa, Ontario, Canada, Canadian Institute for Health Information, 2008
3. Rivera F, Lopez-Gomez JM, Perez-Garcia R: Frequency of renal pathology in Spain 1994-1999. Nephrol Dial Transplant 17: 1594-1602, 2002
4. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, Sasdelli M, Redaelli B, Grassi C, Pozzi C, et al.: A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 48: 1600-1604, 1995
5. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V: A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18: 1899-1904, 2007
6. Hofstra JM, Branten AJ, Wirtz JJ, Noordzij TC, du Buf-Vereijken PW, Wetzels JF: Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: A randomized controlled trial. Nephrol Dial Transplant 25: 129-136
7. Goumenos DS: What have we learned from the use of cyclosporin A in the treatment of nephrotic patients with idiopathic membranous nephropathy? Expert Opin Pharmacother 9: 1695-1704, 2008
8. Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G: Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review. Am J Kidney Dis 44: 385-401, 2004
9. Cameron JS: Membranous nephropathy-Still a treatment dilemma. N Engl J Med 327: 638-639, 1992
10. Cattran D: Management of membranous nephropathy: When and what for treatment. J Am Soc Nephrol 16: 1188-1194, 2005
11. Glassock RJ: The treatment of idiopathic membranous nephropathy: A dilemma or a conundrum? Am J Kidney Dis 44: 562-566, 2004
12. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354: 359-364, 1999
13. Nair R, Bell JM, Walker PD: Renal biopsy in patients aged 80 years and older. Am J Kidney Dis 44: 618-626, 2004
14. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernández-Juárez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernández-Vega F, Praga M; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Españ ola de Nefrología: Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 21: 697-704
15. Toll DB, Janssen KJ, Vergouwe Y, Moons KG: Validation, updating and impact of clinical prediction rules: A review. J Clin Epidemiol 61: 1085-1094, 2008
16. Regional program for the study of glomerulonephritis. Central Committee of the Toronto Glomerulonephritis Registry. CMAJ 124: 158-161, 1981
17. Ponticelli C, Passerini P, Altieri P, Locatelli F, Pappalettera M: Remissions and relapses in idiopathic membranous nephropathy. Nephrol Dial Transplant 7[Suppl 1]: 85-90, 1992
18. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL; North America Nephrotic Syndrome Study Group: Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int 59: 1484-1490, 2001
19. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976
20. Verbraecken J, Van de Heyning P, De Backer W, Van Gaal L: Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism 55: 515-524, 2006
21. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC: Idiopathic membranous nephropathy: Definition and relevance of a partial remission. Kidney Int 66: 1199-1205, 2004
22. Drake C, Fisher L: Prognostic models and the propensity score. Int J Epidemiol 24: 183-187, 1995
23. Weitzen S, Lapane KL, Toledano AY, Hume AL, Mor V: Principles for modeling propensity scores in medical research: A systematic literature review. Pharmacoepidemiol Drug Saf 13: 841-853, 2004
24. Gu XS, Rosenbaum PR: Comparison of multivariate matching methods: Structures, distances, and algorithms. J Comput Graph Stat 2: 405-420, 1993
25. Passerini P, Pasquali S, Cesana B, Zucchelli P, Ponticelli C: Long-term outcome of patients with membranous nephropathy after complete remission of proteinuria. Nephrol Dial Transplant 4: 525-529, 1989
26. Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342: 1887-1892, 2000
27. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women's Health Initiative Investigators: Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349: 523-534, 2003
28. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543-551, 2004
29. Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI, Tektonidou MG, Contopoulos-Ioannidis DG, Lau J: Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 286: 821-830, 2001
30. Zent R, Nagai R, Cattran DC: Idiopathic membranous nephropathy in the elderly: A comparative study. Am J Kidney Dis 29: 200-206, 1997
31. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, Pasquali S, Imbasciati E, Grassi C, Redaelli B, et al.: A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 320: 8-13, 1989
32. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289: 2560-2572, 2003
33. Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Passerini P, Grassi C, Limido D, Pasquali S, Volpini T, et al.: Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 310: 946-950, 1984
34. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, Farina M, Bellazzi R: A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9: 444-450, 1998
35. Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DN, Clark WF, Morrin PA, Lavoie S: A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int 47: 1130-1135, 1995
36. A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. N Engl J Med 301: 1301-1306, 1979
37. Cameron JS, Healy MJ, Adu D: The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. Q J Med 74: 133-156, 1990
38. Cattran DC, Delmore T, Roscoe J, Cole E, Cardella C, Charron R, Ritchie S: A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med 320: 210-215, 1989
39. Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF: Mycophenolate mofetil in idiopathic membranous nephropathy: A clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 50: 248-256, 2007
40. Goumenos DS, Ahuja M, Davlouros P, El Nahas AM, Brown CB: Prednisolone and azathioprine in membranous nephropathy: A 10-year follow-up study. Clin Nephrol 65: 317-323, 2006
41. Rosenbaum PR, Rubin DB: The bias due to incomplete matching. Biometrics 41: 103-116, 1985
42. Benseler SM, Bargman JM, Feldman BM, Tyrrell PN, Harvey E, Hebert D, Silverman ED: Acute renal failure in paediatric systemic lupus erythematosus: Treatment and outcome. Rheumatology (Oxford) 48: 176-182, 2009
43. Ahmad M, Cole EH, Cardella CJ, Cattran DC, Schiff J, Tinckam KJ, Kim SJ: Impact of deceased donor diabetes mellitus on kidney transplant outcomes: A propensity scorematched study. Transplantation 88: 251-260, 2009
44. Rioux JP, Lessard M, De Bortoli B, Roy P, Albert M, Verdant C, Madore F, Troyanov S: Pentastarch 10% (250 kDa/0.45) is an independent risk factor of acute kidney injury following cardiac surgery. Crit Care Med 37: 1293-1298, 2009